President-elect until 2012; President until 2014; Past-President until 2016
Barbara Sahakian is a Professor of Clinical Neuropsychology at The University of Cambridge Department of Psychiatry and MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, where she directs a laboratory of human psychopharmacology. She has an international reputation in the field of psychopharmacology and related disciplines with over 24,500 citations to her published work and an H index of 97. She is perhaps best known for her work on cognitive enhancement using pharmacological treatments, early detection of Alzheimer's disease, cognition and depression and neuroethics. She was one of the first researchers to suggest that attentional dysfunction in Alzheimer's disease could be ameliorated using pharmacotherapy, such as cholinesterase inhibitors. She has over 375 publications covering these topics in scientific journals, including Science, Nature, Nature Neuroscience, Annual Reviews of Neuroscience, Archives of General Psychiatry, Biological Psychiatry, Psychological Medicine, Journal of Psychopharmacology, Psychopharmacology, Neuropsychopharmacology, International Journal of Neuropsychopharmacology and Neuroscience and Biobehavioural Reviews. She is also on the Editorial Board of several of these journals. In terms of peer esteem, she has been a member of the Medical Research Council Neurosciences and Mental Health Board (2006 -2010), a member of the Science Coordination Team for the UK Government Foresight Project on Mental Capital and Wellbeing (2008) and a member of the Society for Neuroscience (SfN) Committee on Women in Neuroscience. She has just been appointed to the Scientific Advisory Board for Grand Challenges in Global Mental Health. She has been given a number of honours, including the FC Donders Chair in Psychopharmacology (Utrecht University, 2005), Fellow of the Academy of Medical Sciences (2004-), Distinguished International Scholars Award (University of Pennsylvania, 2009-2010), Plenary lectures at the Annual Meetings of ECNP (Barcelona, 2008) and CINP (Hong Kong, 2010) and a Lecture for the President's Teaching Day at ACNP.
She was President of BAP (2012-2014), is a member of BAP Council and has been a regular contributor to BAP through organizing, chairing and speaking in Symposia and Workshops at the Annual Meetings. She has a strong interest in training young psychopharmacologists and a number of her current and previous PhD students are also members of BAP and participate in BAP events. She is committed to a translational approach to neuropsychopharmacology. Indeed, her current programme of research funded by the Wellcome Trust and Medical Research Council investigates the neurochemical modulation of impulsive and compulsive disorders, such as attention deficit hyperactivity disorder and obsessive compulsive disorder, using a translational medicine approach. She has extensively promoted the engagement of the public in science through communication with the media and participation in science festivals and many public lectures. She is currently President of the International Neuroethics Society. She is co-author of ‘Bad Moves. How decision making goes wrong and the ethics of smart drugs.’ (Oxford University Press, 2013) and co-editor of The Oxford Handbook of Neuroethics (Oxford University Press, 2011).She is a member of the World Economic Forum (WEF) Global Agenda Council on Brain Research. She recently presented on neuroscience and mental health at the WEF 2014 in Davos.
Declaration of Interests
Have you, in the past three years, had patent/s or invention/s from which you may derive personal benefit in the area of psychopharmacology?
Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one’s own name, or those of dependent family members.)
Shares in CeNeS. Share options in Cambridge Cognition
Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
Servier, Lundbeck, Otsuka, Cambridge Cognition
Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
Have you, in the past three years, had membership of the speakers’ bureau for any company?
Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
Have you, in the past three years, recruited patients for industry-sponsored studies?
No. However, I have recruited patients for an investigator driven study funded by industry
Form completed on 4th February 2015
Subscribe to the News Feed